Rivaroxaban: can we trust the monitoring device ?
The BMJ must continue its campaign for open access to RCT data, without fear or favour (http://www.bmj.com/content/350/bmj.h3337).
Sadly, in an intensely competitive Pharma world, the companies are unlikely to throw open their most intimate secrets.. but they could confirm how accurately their INR data was lab-validated ??
At least the Rocket-AF triallists have reviewed the effect of the recalled device, thus - http://www.nejm.org/doi/full/10.1056/NEJMc1515842?query=featured_home
Competing interests: No competing interests